Institut Gustave Roussy

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.

MADRID — Selpercatinib improved outcomes compared with cabozantinib or vandetanib for treatment of RET-mutant medullary thyroid cancer, according to randomized phase 3 study results presented at ESMO Congress.

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

CHICAGO — Adding talazoparib to enzalutamide reduced the risk for disease progression or death by 55% in certain men with metastatic castration-resistant prostate cancer, results of the randomized phase 3 TALAPRO-2 trial showed.

CHICAGO — Ivosidenib extended median OS more than three times longer than placebo when added to azacitidine for adults with treatment-naive, IDH1-mutated acute myeloid leukemia, according to updated results of the phase 3 AGILE trial.

GENEVA — Women who used low-dose aspirin did not exhibit reduced risk for breast cancer, according to study results presented at World Cancer Congress.

Genomic sequencing of tumors enabled 107 patients with pediatric cancer who experienced relapse to receive an appropriate matched therapy that is not standard of care, according to study results reported in Cancer Discovery.

A follow-up strategy without radioiodine appeared noninferior to an ablation strategy with radioiodine among patients with low-risk thyroid cancer undergoing thyroidectomy, according to study results in The New England Journal of Medicine.

SAN FRANCISCO — Lenvatinib plus pembrolizumab did not demonstrate a positive benefit-risk ratio compared with pembrolizumab and placebo as first-line therapy for certain patients with advanced urothelial carcinoma, study results showed.

The addition of ivosidenib to azacitidine improved outcomes for certain patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.